Patients gain potential options for treatment of advanced NSCLC
This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, trials show that ivonescimab combined with chemotherapy improved overall survival, and sunvozertinib improved progression‐free survival. In addition, adjuvant selpercatinib improved event...